Standout Papers

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease 2017 2026 2020 2023 359
  1. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (2017)
    Ian Pavord, Pascal Chanez et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 53 standout
Sub-graph 1 of 23

Citing Papers

GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
2025 StandoutNature
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
2025 Standout
1 intermediate paper

Works of Stephanie Harris being referenced

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
2017 Standout

Author Peers

Author Last Decade Papers Cites
Stephanie Harris 586 543 36 90 11 737
Ha Nguyen 355 403 67 37 12 713
Sumiko Shingo 329 426 52 26 18 679
Dorothy J. Margolskee 457 622 76 51 15 745
Benjamin Hartley 606 398 40 39 14 742
Andrew R. Fischer 310 510 43 32 7 632
Eleanor M. Dunican 402 402 84 54 13 694
Keith Hattotuwa 546 408 58 131 10 768
Michael J. Kraemer 337 320 39 73 19 749
Helen Barnacle 538 448 53 30 9 641
Nicoletta De Marzo 315 349 109 33 24 817

All Works

Loading papers...

Rankless by CCL
2026